Argatroban
CLINICAL USE
Anticoagulant:
in patients with heparin-induced
thrombocytopenia (HIT)
undergoing percutaneous coronary
intervention
DOSE IN NORMAL RENAL FUNCTION
treatment of thrombosis: infusion of
2 mcg/kg/min; adjust according to
response (APTT); maximum
10 mcg/kg/min
percutaneous coronary intervention:
initially a bolus of 350 mcg/kg
administered via a large bore IV line over
3–5 minutes, followed by an infusion of
25 mcg/kg/min. Additional IV bolus doses
of 150 mcg/kg may be given if required and
the infusion rate changed to
15–40 mcg/kg/min
PHARMACOKINETICS
508.6
54
16
0.17
39–51 minutes/
Unchanged
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
Unlikely to be dialysed. Dose as in
normal renal function
Not dialysed. Dose as in normal renal function
Not dialysed. Dose as in normal renal function
Unlikely to be dialysed. Dose as in
normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
administration
bleeding
bleeding complications; enhance effect of
argatroban
risk of bleeding complications
ADMINISTRATION
Reconstition
–
Route
IV
Rate of Administration
Bolus: over 3–5 minutes
Infusion: 2–25 mcg/kg/min
Comments
96 hours if refrigerated or at controlled
room temperature and protected from
light
0.9%, glucose 5% or Lactated Ringer’s
solution, i.e. 250 mg (2.5 mL) into 250 mL
of diluent. The solution must be mixed by
inversion for 1 minute
OTHER INFORMATION
anticoagulation: 0.1 mg/kg bolus, followed
by a continuous infusion of 0.1-0.2 mg/kg/
hour, dosing being adjusted to maintain an
APTT 1.5–3 times normal.
was suggested, dosing being adjusted to
maintain an APTT 1.5–2 times normal.
4 hour dialysis session
major bleeding